全文获取类型
收费全文 | 1736671篇 |
免费 | 129556篇 |
国内免费 | 4701篇 |
专业分类
耳鼻咽喉 | 22061篇 |
儿科学 | 56668篇 |
妇产科学 | 47279篇 |
基础医学 | 246414篇 |
口腔科学 | 49833篇 |
临床医学 | 155165篇 |
内科学 | 343845篇 |
皮肤病学 | 39474篇 |
神经病学 | 135345篇 |
特种医学 | 65496篇 |
外国民族医学 | 243篇 |
外科学 | 262983篇 |
综合类 | 40962篇 |
现状与发展 | 5篇 |
一般理论 | 534篇 |
预防医学 | 126393篇 |
眼科学 | 40751篇 |
药学 | 127293篇 |
15篇 | |
中国医学 | 5435篇 |
肿瘤学 | 104734篇 |
出版年
2021年 | 14531篇 |
2019年 | 14680篇 |
2018年 | 21300篇 |
2017年 | 16291篇 |
2016年 | 17764篇 |
2015年 | 20435篇 |
2014年 | 28143篇 |
2013年 | 40271篇 |
2012年 | 55896篇 |
2011年 | 58621篇 |
2010年 | 34644篇 |
2009年 | 32405篇 |
2008年 | 54138篇 |
2007年 | 57464篇 |
2006年 | 57678篇 |
2005年 | 54905篇 |
2004年 | 52874篇 |
2003年 | 49984篇 |
2002年 | 48047篇 |
2001年 | 92763篇 |
2000年 | 94578篇 |
1999年 | 77896篇 |
1998年 | 20180篇 |
1997年 | 17609篇 |
1996年 | 17724篇 |
1995年 | 17009篇 |
1994年 | 15537篇 |
1993年 | 14267篇 |
1992年 | 57874篇 |
1991年 | 55660篇 |
1990年 | 53388篇 |
1989年 | 51168篇 |
1988年 | 46463篇 |
1987年 | 45260篇 |
1986年 | 42545篇 |
1985年 | 40238篇 |
1984年 | 29564篇 |
1983年 | 25082篇 |
1982年 | 14006篇 |
1979年 | 25703篇 |
1978年 | 17684篇 |
1977年 | 14993篇 |
1976年 | 13949篇 |
1975年 | 14641篇 |
1974年 | 17745篇 |
1973年 | 17060篇 |
1972年 | 15776篇 |
1971年 | 14541篇 |
1970年 | 13498篇 |
1969年 | 12589篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
12.
Qiangsheng He Chongfei Huang Xiwen Qin Yuanyuan Yu Di Tang Junjie Huang Zi Chong Kuo Yuyao Ling Deli Mao Bin Xia Wenjing Li Kuiqing Lu Man Yang Yulong He Wenbo Meng Jinqiu Yuan Yihang Pan 《International journal of cancer. Journal international du cancer》2023,153(5):942-949
Recent epidemiological studies suggested that proton pump inhibitor (PPI) use was associated with an increased risk of biliary tract cancer (BTC), however, confounders were not adequately controlled. Our study aimed to evaluate PPI use and subsequent risk of BTC and its subtypes in three well-established cohorts. We conducted a pooled analysis of the subjects free of cancers in UK Biobank (n = 463 643), Nurses' Health Study (NHS, n = 80 235) and NHS II (n = 95 869). Propensity score weighted Cox models were used to estimate marginal HRs of PPIs use on BTC risk, accounting for potential confounders. We documented 284 BTC cases in UK Biobank (median follow-up: 7.6 years), and 91 cases in NHS and NHS II cohorts (median follow-up: 15.8 years). In UK biobank, PPI users had a 96% higher risk of BTC compared to nonusers in crude model (HR 1.96, 95% CI 1.44-2.66), but the effect was attenuated to null after adjusting for potential confounders (HR 0.95, 95% CI 0.60-1.49). PPI use was not associated with risk of BTC in the pooled analysis of three cohorts (HR 0.93, 95% CI 0.60-1.43). We also observed no associations between PPI use with risk of intrahepatic (HR 1.00, 95% CI 0.49-2.04), extrahepatic bile duct (HR 1.09, 95% CI 0.52-2.27) and gallbladder cancers (HR 0.66, 95% CI 0.26-1.66) in UK Biobank. In summary, regular use of PPIs was not associated with the risk of BTC and its subtypes. 相似文献
13.
Comprehensive evidence regarding the treatment of non-anaemic iron deficiency in patients undergoing valvular heart surgery is lacking. This study aimed to investigate the association between non-anaemic iron deficiency and postoperative outcomes in these patients. We retrospectively analysed 321 patients of which 180 (56%) had iron deficiency (defined as serum ferritin < 100 ng.ml-1 or < 300 ng.ml-1 with transferrin saturation < 20%). While the iron-deficient group had lower pre-operative haemoglobin levels than the non-iron deficient group (median (IQR [range]) 134 (127–141 [120–172]) g.l-1, 143 (133–150 [120–179]) g.l-1, p = 0.001), there was no between-group difference in allogeneic red blood cell transfusion. Median (IQR [range]) days alive and out of hospital at postoperative day 90 was 1 day shorter in the iron-deficient group (80 (77–82 [9–85]) days vs. 81 (79–83 [0–85]) days, p = 0.026). In multivariable analysis, only cardiopulmonary bypass duration (p = 0.032) and intra-operative allogeneic red blood cell transfusion (p = 0.011) were significantly associated with reduced days alive and out of hospital at postoperative day 90. Iron deficiency did not exert any adverse influence on secondary outcomes except length of hospital stay. Our findings indicate that non-anaemic iron deficiency alone is not associated with adverse effects in patients undergoing valvular heart surgery when it does not translate into an increased risk of allogeneic transfusion. 相似文献
14.
多囊卵巢综合征(polycystic ovary syndrome,PCOS)是一种内分泌代谢紊乱综合征,临床表现高度异质性。肥胖是PCOS异质性临床表现之一,超过50%的PCOS患者超重或肥胖。肥胖型PCOS主要表现为高雄激素血症、中心型肥胖和糖脂代谢紊乱,非肥胖型PCOS主要表现为黄体生成激素(luteinizing hormone,LH)水平异常升高。尽管肥胖型和非肥胖型PCOS均存在内分泌代谢异常,然而肥胖可加重PCOS糖脂代谢紊乱;肥胖型PCOS还表现脂肪代谢的异常。综述肥胖型PCOS患者的临床特征、性激素水平、糖脂代谢特征,旨在为肥胖型和非肥胖型PCOS患者新的分型诊治提供参考。 相似文献
15.
16.
Clinical & Experimental Metastasis - 相似文献
17.
18.
19.
20.
Adjuvant irradiation is the standard treatment after breast conservative surgery. Normofractionated regimen with an overall treatment time of 5 to 6 weeks is often considered as a limiting factor for irradiation compliance. In order to answer this issue, moderate and more recently extreme hypofractionated protocols appeared. We report here oncological outcomes and toxicity of hypofractionated breast irradiation. After defining the frame of moderate and extreme hypofractionated breast irradiations based on overall treatment time, patient selection criteria were listed. According to their levels of proof, the results of moderate and extreme hypofractionated breast irradiation were analysed. Overall treatment time for moderate hypofractionated breast irradiation ranged from 3 to 4 weeks, while for extreme hypofractionated breast irradiation, it was less than 1 week. For moderate hypofractionated breast irradiation, whole breast irradiation was currently performed with or without lymph node irradiation. Moderate hypofractionated breast irradiation has proven to be as safe and as efficient as normofractionated breast irradiation with level IA evidence. For extreme hypofractionated breast irradiation, phase III randomized trials confirmed that accelerated partial breast irradiation was non-inferior in terms of local control compared to normofractionated whole breast irradiation (with external beam radiation therapy and multicatheter brachytherapy), with similar acute and late toxicity. While the use of intraoperative breast irradiation remains under debate, new very accelerated partial breast irradiation (overall treatment time not exceeding 2 days) protocols emerged with encouraging results. Accelerated partial breast irradiation is warranted for extreme hypofractionated breast irradiation and is indicated for low-risk breast cancers. Moderate and extreme hypofractionated breast irradiation regimens are validated and can be routinely proposed according to patient selection criteria. 相似文献